The trajectory of Viagra presents a challenging picture for shareholders. While the initial release generated substantial returns, the lapse of its exclusive rights opened the floodgates to generic alternatives, https://bookmarksurl.com/story7303838/sildenafil-and-big-pharma-a-risky-opportunity